OdySight mobile app reliably measures visual acuity in retina patients at home
Click Here to Manage Email Alerts
Key takeaways:
- Results showed a high level of concordance between OdySight and standard ETDRS measurements.
- The average difference between methods was 0.33 letters.
Tilak Healthcare has released positive data from its TIL002 study of the OdySight mobile app, a vision-monitoring tool for patients with retinal diseases.
“TIL002 marks a key step in the clinical validation of OdySight and proves that it is a reliable way for patients to monitor their visual acuity by themselves at home,” Jean-François Girmens, MD, Tilak’s medical director and co-founder, said in a company press release. “In addition, given the variability of visual acuity measurements, having a large number of results from regular home tests could prove more helpful than occasional measurements performed during consultations taking place a long time apart.”
According to the release, OdySight is a prescription-only medical tool available on smartphones and tablets that allows patients with age-related macular degeneration to monitor visual acuity through self-conducted eye tests. The results are automatically sent to their physicians, alerting them if deterioration is detected.
In the prospective, multicenter TIL002 study, researchers examined 105 eyes from 58 patients over 1.5 years at three centers in France. Analysis of 89 eyes showed a high level of concordance between OdySight and standard ETDRS measurements, with an average difference of 0.33 letters, the release stated. In addition, 82% of OdySight measurements had a maximum difference of nine letters compared with standard test results.
Collapse
Press Release
Read more about
Click Here to Manage Email Alerts